LinkinLegal
Catherine Polizzi photo

Catherine Polizzi

Catherine M. Polizzi Ph.D. | Morrison Foerster Intellectual versatility combined with incisive, pragmatic counseling and business acumen is the hallmark of Catherine’s practice. Catherine helps emerging and established companies through the challenging process of obtaining patents, and provides strategic, effective portfolio counseling and management, as well as strategic advice surrounding freedom of operation and other forms of IP assessment. She develops valuable, strategic portfolios around breakthrough therapies in a variety of areas including cancer, cancer immunotherapy, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular diseases, metabolic disorders, and neurodegenerative diseases such as Alzheimer’s disease. She also has significant experience in a wide spectrum of technology areas, including biologics (such as antibodies, antibody-drug conjugates (ADC), and polypeptides), nucleic acids, precision medicine, diagnostics, cell therapy including T cell technologies, such as chimeric antigen receptors, drug formulation technologies, drug delivery technologies, such as nanotechnologies, microfluidics, drug screening systems, AI solutions for life sciences including discovery platforms, amplification technologies, genetic screening, sequencing technologies including next generation sequencing, regenerative medicine, nutraceuticals, spectroscopy, and organic chemistry, including small molecule drugs. Catherine’s unique background, ability to integrate IP with a given business model to translate into meaningful valuation, risk assessment and advice, and highly effective communication skills in critical settings such as R&D, all phases of product development, and investment contexts, enable her to provide effective, creative solutions to the significant challenges often faced by clients. Catherine is an acquisition and value enhancement driver as well, a critical conduit for companies as they grow from startup through IPO, exit, and beyond. · Morrison Foerster

United StatesHealthcare, Life Sciences

About

Catherine Polizzi helps emerging and established companies through the patent process and provides strategic portfolio counseling. She is recognized as a leading partner in Intellectual Property, Healthcare, and Life Sciences.

Practice areas

HealthcareLife SciencesIntellectual PropertyPatent Prosecution

Office

United States

Morrison Foerster · Catherine M. Polizzi Ph.D. | Morrison Foerster Intellectual versatility combined with incisive, pragmatic counseling and business acumen is the hallmark of Catherine’s practice. Catherine helps emerging and established companies through the challenging process of obtaining patents, and provides strategic, effective portfolio counseling and management, as well as strategic advice surrounding freedom of operation and other forms of IP assessment. She develops valuable, strategic portfolios around breakthrough therapies in a variety of areas including cancer, cancer immunotherapy, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular diseases, metabolic disorders, and neurodegenerative diseases such as Alzheimer’s disease. She also has significant experience in a wide spectrum of technology areas, including biologics (such as antibodies, antibody-drug conjugates (ADC), and polypeptides), nucleic acids, precision medicine, diagnostics, cell therapy including T cell technologies, such as chimeric antigen receptors, drug formulation technologies, drug delivery technologies, such as nanotechnologies, microfluidics, drug screening systems, AI solutions for life sciences including discovery platforms, amplification technologies, genetic screening, sequencing technologies including next generation sequencing, regenerative medicine, nutraceuticals, spectroscopy, and organic chemistry, including small molecule drugs. Catherine’s unique background, ability to integrate IP with a given business model to translate into meaningful valuation, risk assessment and advice, and highly effective communication skills in critical settings such as R&D, all phases of product development, and investment contexts, enable her to provide effective, creative solutions to the significant challenges often faced by clients. Catherine is an acquisition and value enhancement driver as well, a critical conduit for companies as they grow from startup through IPO, exit, and beyond.

United States

Expertise

Cancer ImmunotherapyAutoimmune DiseasesInflammatory DiseasesInfectious DiseasesCardiovascular DiseasesMetabolic DisordersNeurodegenerative DiseasesAlzheimer's DiseaseBiologicsAntibody-Drug ConjugatesPrecision MedicineDiagnosticsCell TherapyChimeric Antigen ReceptorsDrug Formulation TechnologiesDrug Delivery TechnologiesNanotechnologiesMicrofluidicsDrug Screening SystemsAI for Life SciencesAmplification TechnologiesGenetic ScreeningSequencing TechnologiesNext Generation SequencingRegenerative MedicineNutraceuticalsSpectroscopyOrganic ChemistrySmall Molecule Drugs